Skip to main content
Year archive

Novartis AG — 2019 filings

All 66 regulatory filings released by Novartis AG (NOVN) in 2019, sourced directly from the official regulator.

66 Filings
2019 Period
2019 filings (66)
Filing Released Lang
SC TO-T/A Filing
Regulatory Filings
2019-12-23 English
SC TO-T/A Filing
Regulatory Filings
2019-12-19 English
FORM 6-K
Foreign Filer Report
2019-12-16 English
FORM 6-K
Foreign Filer Report
2019-12-05 English
SC TO-T Filing
Regulatory Filings
2019-12-05 English
FORM 6-K
Foreign Filer Report
2019-11-25 English
SC TO-C Filing
Regulatory Filings
2019-11-25 English
SC TO-C Filing
Regulatory Filings
2019-11-25 English
FORM 6-K
Foreign Filer Report
2019-11-15 English
FORM 4 SUBMISSION
Director's Dealing
2019-11-12 English
FORM 3 SUBMISSION
Director's Dealing
2019-11-06 English
FORM 6-K
Foreign Filer Report
2019-11-01 English
FORM 6-K
Foreign Filer Report
2019-10-30 English
6-K
Foreign Filer Report
2019-10-22 English
Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
Earnings Release Q3 2019
2019-10-22 English
FORM 6-K
Foreign Filer Report
2019-10-08 English
Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
Regulatory Filings
2019-10-08 English
FORM 6-K
Foreign Filer Report
2019-10-02 English
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
Regulatory Filings
2019-10-02 English
FORM 6-K
Foreign Filer Report
2019-09-30 English
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
Earnings Release Q3 2019
2019-09-29 English
FORM 6-K
Foreign Filer Report
2019-09-17 English
Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
Legal Proceedings Report
2019-09-17 English
FORM 6-K
Foreign Filer Report
2019-08-30 English
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
Regulatory Filings
2019-08-30 English
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
Regulatory Filings
2019-08-30 English
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
Earnings Release Q3 2019
2019-08-30 English
FORM 6-K
Foreign Filer Report
2019-07-29 English
Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
Regulatory Filings
2019-07-29 English
6-K
Foreign Filer Report
2019-07-18 English
Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased
Earnings Release Q2 2019
2019-07-18 English
FORM 6-K
Foreign Filer Report
2019-07-01 English
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
Regulatory Filings
2019-07-01 English
FORM 6-K
Foreign Filer Report
2019-06-07 English
Novartis announces new leader of Pharmaceuticals Business Unit
Board/Management Information
2019-06-07 English
SD
Regulatory Filings
2019-05-31 English
4
Director's Dealing
2019-05-31 English
FORM 6-K
Foreign Filer Report
2019-05-28 English
FORM 6-K
Foreign Filer Report
2019-05-24 English
FORM 6-K
Foreign Filer Report
2019-05-24 English
3
Director's Dealing
2019-05-23 English
FORM 6-K
Foreign Filer Report
2019-05-09 English
PRIMARY DOCUMENT
Director's Dealing
2019-04-29 English
PRIMARY DOCUMENT
Director's Dealing
2019-04-25 English
6-K
Foreign Filer Report
2019-04-24 English
Novartis starts 2019 with strong sales and double digit core1 operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded
Earnings Release Q1 2019
2019-04-24 English
PRIMARY DOCUMENT
Director's Dealing
2019-04-16 English
PRIMARY DOCUMENT
Director's Dealing
2019-04-11 English
PRIMARY DOCUMENT
Director's Dealing
2019-04-05 English
PRIMARY DOCUMENT
Director's Dealing
2019-04-03 English
PRIMARY DOCUMENT
Director's Dealing
2019-04-03 English
PRIMARY DOCUMENT
Director's Dealing
2019-03-28 English
FORM 6-K
Foreign Filer Report
2019-03-27 English
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Regulatory Filings
2019-03-27 English
FORM 6-K
Foreign Filer Report
2019-03-22 English
PRIMARY DOCUMENT
Director's Dealing
2019-03-15 English
FORM 6-K
Foreign Filer Report
2019-03-14 English
FORM 6-K
Foreign Filer Report
2019-02-26 English
Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
Earnings Release FY 2018
2019-02-25 English
PRIMARY DOCUMENT
Director's Dealing
2019-02-14 English
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2018
Report Publication Announcement
2019-01-30 English
6-K
Foreign Filer Report
2019-01-30 English
6-K
Foreign Filer Report
2019-01-30 English
Regulatory Filings 2019
Regulatory Filings
2019-01-30 English
20-F
Annual Report FY 2018
2019-01-30 English
Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
Earnings Release FY 2018
2019-01-30 English